Drug Profile
Research programme: Bcl-2 inhibitors - AbbVie/Genentech/WEHI
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Abbott Laboratories; Genentech; Walter and Eliza Hall Institute of Medical Research
- Developer AbbVie; Genentech; Walter and Eliza Hall Institute of Medical Research
- Class Small molecules
- Mechanism of Action Proto-oncogene protein c-bcl-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Australia
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
- 08 Feb 2007 Preclinical trials in Cancer in Australia (unspecified route)